Enfortumab Vedotin

No information is available on the clinical use of enfortumab vedotin during breastfeeding. Because enfortumab is a large protein molecule with a molecular weight of about 152,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Vedotin (monomethyl auristatin E) is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during enfortumab vedotin therapy and for at least 3 weeks after the last dose.